Search

Displaying results 5411 - 5420 of 10000 in total
  1. Drug

    Diaminopropanol tetraacetic acid

    go.drugbank.com/drugs/DB12362
    ApprovedWithdrawn

    Diaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others.

  2. Drug

    Dalantercept

    go.drugbank.com/drugs/DB14988
    Investigational

    Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).

  3. Drug

    Livoletide

    go.drugbank.com/drugs/DB15188
    Investigational

    Livoletide is under investigation in clinical trial NCT03790865 (Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome).

  4. Drug

    Methylprednisone

    go.drugbank.com/drugs/DB12952
    ApprovedInvestigationalWithdrawn

    Methylprednisone has been used in trials studying the treatment of Leukemia, Rheumatoid Arthritis, Renal Transplantation, Kidney Transplantation, and Acute Lymphocytic Leukemia, among others.

  5. Drug

    Dotinurad

    go.drugbank.com/drugs/DB16145
    Investigational

    Dotinurad is under investigation in clinical trial NCT03372200 (Febuxostat-controlled, Double-blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout).

  6. Drug

    Neramexane

    go.drugbank.com/drugs/DB04926
    Investigational

    Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.

  7. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  8. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug. … AI-128 is the first human demonstration of sustained release drug administration in the lung.

  9. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    [A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions. … NSAIDs and/or opioids) in this patient population.[A241165] NGF was first discovered in the 1950s[A241180] and was the first neurotrophic factor to be identified and biochemically characterized.

  10. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

    go.drugbank.com/drugs/DB10284
    ApprovedInvestigational

    It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily